Ted Mikuls, MD, MSPH, Stokes-Shackleford professor of rheumatology, vice chair for research, internal medicine at the University of Nebraska, explains how lower extremity amputation among US veterans with gout was independent of body mass index (BMI) and other risk factors.
Ted Mikuls, MD, MSPH, Stokes-Shackleford professor of rheumatology, vice chair for research, internal medicine at the University of Nebraska, explains how lower extremity amputation among US veterans with gout was independent of body mass index (BMI) and other risk factors.
Transcript
Gout was associated with a 20% increase in the rate of lower extremity amputation, and patients with gout were more likely to have high BMI. Is this an important factor?
We actually included BMI as a covariate in the analysis. In other words, we accounted for differences in BMI, at least at baseline. The finding presented—the 20% increase in the rate of lower extremity amputation in gout patients—was independent of body mass index, at least at baseline. So, while BMI is a really important variable, and we know that gout patients more often suffer from obesity, the findings we're seeing appear to be independent of that. We have these patients that were matched based on age and sex. We accounted for that through that matching process, so the findings are independent of age, sex, year of the study, essentially, and then many other factors, including BMI and also including comorbidities that have been associated with amputation such as diabetes, high blood pressure, cardiovascular disease, cancers, and cigarette smoking was another factor we included in that. [The findings are] independent of all those other risk factors.
Transcript edited for clarity.
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
June 19th 2025Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Read More